SCHEMBL24011560

SCHEMBL24011560

COc1ccc(CNC(=O)NC2CCC(C(=O)N3CCC3c3ccccc3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ MCHR1 Q99705 4/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.52
▸ DRD4 P21917 1/20 0.47
▸ EPHX1 P07099 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ TSHR P16473 2/20 0.45
▸ SIGMAR1 Q99720 1/20 0.45
▸ GLA P06280 1/20 0.44
▸ PPID Q08752 1/20 0.44
▸ LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24011472 0.94 NPC1 (0.58) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL26633709 0.90 NPC1 (0.52) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011598 0.86 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011343 0.85 LMNA (0.55) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL26633877 0.84 NPC1 (0.53) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011344 0.83 RAB9A (0.61) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011596 0.83 RAB9A (0.58) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011431 0.82 RAB9A (0.61) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011342 0.81 NPC1 (0.57) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011546 0.80 NPC1 (0.68) NPC1RAB9ASMN1; SMN2MCHR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
WO-2021226276-A2 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT NPC1 128/4885RAB9A 814/4885SMN1; SMN2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback